04 October 2019
Visiongain has published a new pharma report Top 50 Gastrointestinal Therapeutic Companies 2020: GlaxoSmithKline, Abbott, Allergan, Eli Lilly, Evoke Pharma, Other Companies.
The gastrointestinal (GI) therapeutics industry is on the rise; growing to reach $68,237.0m by 2028. This growth stems from rising prevalence of GI disorders. Moreover, the increase in R&D has been a priority of the big pharma companies to infuse the drug pipelines with a new set of candidates with a high potential of reaching the clinical stage. However, the pricing pressure due to rising competition has hampered the market growth. On the contrary, the expiry of high-profile patents, which will carve the path for the launch of generic drugs in the market can provide growth opportunities to the other players in the market.
This report profiled the selected companies: Abbott, AbbVie, Alexion Pharmaceuticals, Allergan, ANI Pharmaceuticals, Inc., AstraZeneca, Bayer AG, Biogen, Eisai Co., Ltd., Eli Lilly, Evoke Pharma, GlaxoSmithKline and other companies.
The lead analyst commented that "Emerging economies of Asia-Pacific and LAMEA possess high potential for gastrointestinal drugs. The rise in purchasing power in these economies is expected to augment the market growth. Rise in awareness regarding GI diseases such as, ulcerative colitis, IBD and cancer and the use of novel drugs the treatment of these diseases in the developing regions, have resulted in regulatory authorities in these regions to take key decisions to improve the legislations of gastrointestinal drugs."
Notes for Editors
f you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
26 May 2022
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.